Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Regulatory News & FDA Approvals › GenomeDx Biosciences to Pay $2M to Settle Allegations of Improper Medicare Billing

GenomeDx Biosciences to Pay $2M to Settle Allegations of Improper Medicare Billing

Feb 12, 2019
|
staff reporter

NEW YORK (GenomeWeb) – GenomeDx Biosciences has agreed to pay $1.99 million to settle charges that it improperly billed Medicare for its Decipher Biopsy prostate cancer genomic classifier, the US Attorney's Office for the Southern District of California announced on Monday.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Regulatory News & FDA Approvals

  1. FDA Revises Emergency Use Authorization for Abbott Point-of-Care SARS-CoV-2 Test

  2. CDC Reverses Position, Says Asymptomatic Patients Should Be Tested for SARS-CoV-2

  3. FDA Grants Emergency Use Authorization for GK Pharmaceuticals Coronavirus Test

  4. Mount Sinai Coronavirus Antibody Test Gets NYSDOH Emergency Use Authorization for Quantitative Use

  5. FDA Grants Emergency Use Authorization to Coronavirus Tests From Visby Medical, SNIBE

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.